Mary S. Easton Center for Alzheimer's Disease Research, Department of Neurology, David Geffen School of Medicine at UCLA, Los Angeles, CA 90095-7226, USA.
J Neurol Neurosurg Psychiatry. 2013 Feb;84(2):154-62. doi: 10.1136/jnnp-2011-302087. Epub 2012 Oct 20.
Mutations in the presenilin (PSEN1, PSEN2) and amyloid precursor protein (APP) genes cause familial Alzheimer's disease (FAD) in a nearly fully penetrant, autosomal dominant manner, providing a unique opportunity to study presymptomatic individuals who can be predicted to develop Alzheimer's disease (AD) with essentially 100% certainty. Using tensor-based morphometry (TBM), we examined brain volume differences between presymptomatic and symptomatic FAD mutation carriers and non-carrier (NC) relatives.
Twenty-five mutation carriers and 10 NC relatives underwent brain MRI and clinical assessment. Four mutation carriers had dementia (MUT-Dem), 12 had amnestic mild cognitive impairment (MUT-aMCI) and nine were cognitively normal (MUT-Norm). TBM brain volume maps of MUT-Norm, MUT-aMCI and MUT-Dem subjects were compared to NC subjects.
MUT-Norm subjects exhibited significantly smaller volumes in the thalamus, caudate and putamen. MUT-aMCI subjects had smaller volumes in the thalamus, splenium and pons, but not in the caudate or putamen. MUT-Dem subjects demonstrated smaller volumes in temporal, parietal and left frontal regions. As non-demented carriers approached the expected age of dementia diagnosis, this was associated with larger ventricular and caudate volumes and a trend towards smaller temporal lobe volume.
Cognitively intact FAD mutation carriers had lower thalamic, caudate and putamen volumes, and we found preliminary evidence for increasing caudate size during the predementia stage. These regions may be affected earliest during prodromal stages of FAD, while cortical atrophy may occur in later stages, when carriers show cognitive deficits. Further studies of this population will help us understand the progression of neurobiological changes in AD.
早老素(PSEN1、PSEN2)和淀粉样前体蛋白(APP)基因突变以近乎完全外显、常染色体显性方式导致家族性阿尔茨海默病(FAD),为研究有症状的个体提供了独特的机会,这些个体可以通过预测以几乎 100%的确定性发展为阿尔茨海默病(AD)。我们使用基于张量的形态计量学(TBM)检查了无症状和有症状的 FAD 基因突变携带者与非携带者(NC)亲属之间的脑容量差异。
25 名突变携带者和 10 名 NC 亲属接受了脑部 MRI 和临床评估。4 名突变携带者患有痴呆症(MUT-Dem),12 名患有遗忘型轻度认知障碍(MUT-aMCI),9 名认知正常(MUT-Norm)。将 MUT-Norm、MUT-aMCI 和 MUT-Dem 受试者的 TBM 脑容量图与 NC 受试者进行比较。
MUT-Norm 受试者的丘脑、尾状核和壳核体积明显较小。MUT-aMCI 受试者的丘脑、脑桥和脑桥体积较小,但尾状核和壳核体积没有变化。MUT-Dem 受试者的颞叶、顶叶和左额叶区域体积较小。当非痴呆携带者接近预期的痴呆诊断年龄时,这与更大的脑室和尾状核体积以及颞叶体积减小的趋势有关。
认知正常的 FAD 基因突变携带者的丘脑、尾状核和壳核体积较小,我们初步发现,在痴呆前阶段,尾状核体积增大。这些区域可能在 FAD 的前驱期最早受到影响,而当携带者出现认知缺陷时,皮质萎缩可能发生在后期。对这一人群的进一步研究将帮助我们了解 AD 中神经生物学变化的进展。